The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 16, Issue , 2014, Pages

  Cutolo, Maurizio ^a   Spies, Cornelia M ^b   Buttgereit, Frank ^b   Paolino, Sabrina ^a   Pizzorni, Carmen ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 6; MELATONIN; METHOTREXATE; PLACEBO; PREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; CYTOKINE; TUMOR NECROSIS FACTOR;

ADRENAL INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; CHRONIC INFLAMMATION; CIRCADIAN RHYTHM; CONTROLLED DRUG RELEASE; CORTICOSTEROID RELEASE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; EVENING DOSAGE; GENE REPRESSION; GENOMICS; HUMAN; LOW DRUG DOSE; MORNING DOSAGE; PATHOGENESIS; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; TRANSACTIVATION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DISEASE COURSE; GENE EXPRESSION REGULATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION (PROCESS); SECRETION RATE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CIRCADIAN RHYTHM; CYTOKINES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; RECEPTORS, GLUCOCORTICOID; SECRETORY RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84978831403     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4685     Document Type: Review

References (63)

1. McInnes IB, O'Dell JR: State-of-the-art: rheumatoid arthritis. Ann Rheum Dis. 2010, 69: 1898-1906. 10.1136/ard.2010.134684.
2. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62: 2569-2581. 10.1002/art.27584.
3. Berglin E, Dahlqvist SR: Comparison of the 1987 ACR and 2010 ACR/EULAR classification criteria for rheumatoid arthritis in clinical practice: a prospective cohort study. Scand J Rheumatol. 2013, 42: 362-368. 10.3109/03009742.2013.776103.
4. McInnes IB, Schett G: The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011, 365: 2205-2219. 10.1056/NEJMra1004965.
5. Ceccarelli F, Perricone C, Trotta F, Cuomo G, Pellerito R, Bagnato G, Salaffi F, Caporali R, Cutolo M, Galeazzi M, Fiocco U, Lapadula G, Bombardieri S, Bianchi G, Gorla R, Giardina AR, Gallo G, Giardino AM, Valesini G, Arpa Study Group: Remission in early, aggressive rheumatoid arthritis: a multicentre prospective observational Italian study ARPA (Artrite Reumatoide Precoce Aggressiva). Clin Exp Rheumatol. 2013, 31: 341-349.
6. Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R: Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014, 73: 3-5.
7. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I: Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005, 52: 3360-3370. 10.1002/art.21298.
8. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien Tk, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014, 73: 492-509.
9. Newton R: Anti-inflammatory glucocorticoids: changing concept. Eur J Pharmacol. 2014, 724: 231-236.
10. Stellato C: Posttranscriptional gene regulation: novel pathways for glucocorticoids' anti-inflammatory action. Transl Med UniSa. 2012, 3: 67-73.
11. Strehl C, Spies CM, Buttgereit F: Pharmacodynamics of glucocorticoids. Clin Exp Rheumatol. 2011, 29 (5 Suppl 68): S13-S18.
12. Buttgereit F, da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, Kirwan J, Kohler L, Van Riel P, Vischer T, Bijlsma JW: Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002, 61: 718-722. 10.1136/ard.61.8.718.
13. Almawi WY, Melemedjian OK: Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukocyte Biol. 2002, 71: 9-15.
14. Pratt WB: The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med. 1998, 217: 420-434. 10.3181/00379727-217-44252.
15. Jensen LB, Magnussson E, Gunnarsson L, Vermehren C, Nielsen HM, Petersson K: Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles. Int J Pharm. 2010, 390: 53-60. 10.1016/j.ijpharm.2009.10.022.
16. Stahn C, Buttgereit F: Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008, 4: 525-533.
17. Barnes PJ: Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci. 1998, 94: 557-572.
18. Spies CM, Bijlsma JW, Burmester GR, Buttgereit F: Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol. 2010, 10: 302-307. 10.1016/j.coph.2010.02.001.
19. Coutinho AE, Chapman KE: The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011, 335: 2-13. 10.1016/j.mce.2010.04.005.
20. Alten R, Döring G, Cutolo M, Gromnica-Ihle E, Witte S, Straub R, Buttgereit F: Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J Rheumatol. 2010, 37: 2025-2031. 10.3899/jrheum.100051.
21. Buttgereit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE, SuproniK J, Szombati I, Romer U, Witte S, Saag KG: Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis. 2013, 72: 204-210. 10.1136/annrheumdis-2011-201067.
22. Cutolo M, Iaccarino L, Doria A, Govoni M, Sulli A, Marcassa C: Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids. Clin Exp Rheumatol. 2013, 31: 498-505.
23. Buttgereit F, Scheffold A: Rapid glucocorticoid effects on immune cells. Steroids. 2002, 67: 529-534. 10.1016/S0039-128X(01)00171-4.
24. Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F, Caeyers N, Cutolo M, Halliday S, Da Silva JA, Kirwan JR, Ray D, Rovensky J, Severijns G, Westhovens R, Bijlsma JW: EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013, 72: 1905-1913. 10.1136/annrheumdis-2013-203249.
25. Buttgereit F, Saag KG, Cutolo M, da Silva JA, Bijlsma JW: The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol. 2005, 34: 14-21. 10.1080/03009740510017706.
26. Song IH, Buttgereit F: Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol Cell Endocrinol. 2006, 246: 142-146. 10.1016/j.mce.2005.11.012.
27. Cutolo M: Chronobiology and the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2012, 24: 312-318. 10.1097/BOR.0b013e3283521c78.
28. Cutolo M: Rheumatoid arthritis: circadian and circannual rhythms in RA. Nat Rev Rheumatol. 2011, 7: 500-502. 10.1038/nrrheum.2011.115.
29. Strehl C, Spies CM, Buttgereit F: Pharmacodynamics of glucocorticoids. Clin Exp Rheumatol. 2011, 29 (5 Suppl 68): S13-S18.
30. Spies CM, Cutolo M, Straub RH, Burmester GR, Buttgereit F: Prednisone chronotherapy. Clin Exp Rheumatol. 2011, 29 (5 Suppl 68): S42-S45.
31. Polley HF, Slocumb CH, Ward LE, Hench PS: Recognition and treatment of patients with chronic hypercortisonism. Ann Rheum Dis. 1955, 14: 416-417.
32. Empire Rheumatism Council: Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis. Results up to one year. Ann Rheum Dis. 1955, 14: 353-367.
33. Empire Rheumatism Council: Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis. Results of three years treatment. Ann Rheum Dis. 1957, 16: 277-289.
34. de Andrade JR, McCormick JN, Hill AGS: Small doses of prednisolone in the management of rheumatoid arthritis. Ann Rheum Dis. 1964, 23: 158-162. 10.1136/ard.23.2.158.
35. Pincus T, Cutolo M: Clinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritis. Neuroimmunomodulation. 2015, 22: 46-50. 10.1159/000362734.
36. Pincus T, Bijlsma JW, Braun J, Buttgereit F, Cutolo M: Low-dose glucocorticoids in rheumatic diseases: introduction. Clin Exp Rheumatol. 2011, 29 (5 Suppl 68): S2-S4.
37. Harris ED, Emkey RD, Nichols JE, Newberg A: Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol. 1983, 10: 713-721.
38. Bijlsma JW: Disease control with glucocorticoid therapy in rheumatoid arthritis. Rheumatology (Oxford). 2012, 51 (Suppl 4): iv9-iv13.
39. Hafström I, Albertsson K, Boonen A, van der Heijde D, Landewé R, Svensson B, BARFOT Study Group: Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis. 2009, 68: 508-513. 10.1136/ard.2008.087833.
40. Jacobs JW, van Everdingen AA, Verstappen SM, Bijlsma JW: Follow up radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum. 2006, 54: 1422-1428. 10.1002/art.21809.
41. Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJ, Seys PE, Huizinga TW, Dijkmans BA, Allaart CF: The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt sudy. Ann Rheum Dis. 2011, 70: 1039-1046. 10.1136/ard.2010.141234.
42. van Tuyl LHD, Boers M, Lems WF, Landewe RB, Han H, van der Linden S, van de Laar M, Westhovens R, van Denderen JC, Westedt ML, Peeters AJ, Jacobs P, Huizinga TW, van de Brink H, Dijkmans BA, Voskuyl AE: Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis. 2010, 69: 807-812. 10.1136/ard.2009.108027.
43. Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, Geurts MA, van der Werf JH, van Albada-Kuipers GA, Jahangier-de Veen ZN, van der Veen MJ, Verhoef CM, Lafeber FP, Bijlsma JW, Utrecht Rheumatoid Arthritis Cohort Study Group: Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012, 156: 329-339. 10.7326/0003-4819-156-5-201203060-00004.
44. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I: Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005, 52: 3360-3370. 10.1002/art.21298.
45. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW: Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002, 136: 1-12. 10.7326/0003-4819-136-1-200201010-00006.
46. Goekoop-Ruiterman YPM, Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). A randomized, controlled trial. Arthritis Rheum. 2005, 52: 3381-3390. 10.1002/art.21405.
47. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den Brink HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997, 350: 309-318. 10.1016/S0140-6736(97)01300-7.
48. Landewé RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, van Denderen JC, Westedt ML, Peeters AJ, Dijkmans BA, Jacobs P, Boonen A, van der Heijde DM, van der Linden S: COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002, 46: 347-356. 10.1002/art.10083.
49. van Tuyl LHD, Boers M, Lems WF, Landewé RB, Han H, van der Linden S, van de Laar M, Westhovens R, van Denderen JC, Westedt ML, Peeters AJ, Jacobs P, Huizinga TW, van de Brink H, Dijmans BA, Voskuyl AE: Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis. 2010, 69: 807-812. 10.1136/ard.2009.108027.
50. Cutolo M, Chrousos GP, Pincus T: Special issue on glucocorticoid therapy in rheumatic diseases: introduction. Neuroimmunomodulation. 2015, 22: 3-5. 10.1159/000362737.
51. Pincus T, Sokka T, Castrejón I, Cutolo M: Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthritis Care Res (Hoboken). 2013, 65: 729-736. 10.1002/acr.21899.
52. Cutolo M, Buttgereit F, Straub RH: Regulation of glucocorticoids by the central nervous system. Clin Exp Rheumatol. 2011, 29 (5 Suppl 68): S-19-S-22.
53. Kanczkowski W, Alexaki VI, Tran N, Großklaus S, Zacharowski K, Martinez A, Popovics P, Block NL, Chavakis T, Schally AV, Bornstein SR: Hypothalamo-pituitary and immune-dependent adrenal regulation during systemic inflammation. Proc Natl Acad Sci USA. 2013, 110: 14801-14806. 10.1073/pnas.1313945110.
54. Cutolo M, Foppiani L, Minuto F: Hypothalamic-pituitary-adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica. J Endocrinol Invest. 2002, 25 (10 Suppl): 19-23.
55. Cutolo M, Straub RH: Polymyalgia rheumatica: evidence for a hypothalamic-pituitary-adrenal axis-driven disease. Clin Exp Rheumatol. 2000, 18: 655-658.
56. Cutolo M, Sulli A, Pizzorni C, Craviotto C, Straub RH: Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis. Ann N Y Acad Sci. 2003, 992: 107-117. 10.1111/j.1749-6632.2003.tb03142.x.
57. Cutolo M, Villaggio B, Otsa K, Aakre O, Sulli A, Seriolo B: Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease's symptoms. Autoimmun Rev. 2005, 4: 497-502. 10.1016/j.autrev.2005.04.019.
58. Yoshida K, Hashimoto T, Sakai Y, Hashiramoto A: Involvement of the circadian rhythm and inflammatory cytokines in the pathogenesis of rheumatoid arthritis. J Immunol Res. 2014, 2014: 282495-
59. Straub RH, Cutolo M, Buttegreit F, Pongratz G: Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med. 2010, 267: 543-560. 10.1111/j.1365-2796.2010.02218.x.
60. Straub RH1, Buttgereit F, Cutolo M: Alterations of the hypothalamic-pituitary-adrenal axis in systemic immune diseases - a role for misguided energy regulation. Clin Exp Rheumatol. 2011, 29 (5 Suppl 68): S23-S31.
61. Cutolo M: Hormone therapy in rheumatic diseases. Curr Opin Rheumatol. 2010, 22: 257-263. 10.1097/BOR.0b013e328336ec24.
62. Spies CM, Cutolo M, Straub RH, Burmester GR, Buttgereit F: Prednisone chronotherapy. Clin Exp Rheumatol. 2011, 29 (5 Suppl 68): S42-S45.
63. Clarke LL, Jessop DS, Hunt LP, Straub RH, Perry MG, Kirwan JR: Alleviation of morning joint stiffness by low-dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisol. Int J Clin Rheumatol. 2011, 6: 241-249. 10.2217/ijr.11.12.